ASND Ascendis Pharma A/S

Price Chart

Executive Summary

Citigroup initiated coverage on Ascendis Pharma A/S (ASND) with a Buy rating and a $355 price target, representing 44.6% upside from the current price of $245.49. The new PT tops the Street, surpassing the prior high of $341.98 and sitting 20% above the consensus mean of $295.96. Citigroup's track record shows 55% accuracy on 4,355 calls with a 4.9% average return, placing it in the middle tier among firms covering ASND. Consensus is overwhelmingly bullish — 23 of 24 analysts rate the stock Buy (95.8%), with just one Hold and no Sells. EPS estimates have surged over the past week: current-year EPS is now $10.21 versus $2.82 seven days ago, reflecting strong upward revisions. Institutional buyers are piling in — Two Sigma, Morgan Stanley, and UBS have all significantly added or doubled positions — while short interest sits at 91.5%, a potential squeeze catalyst. However, CEO Flemming Steen Jensen sold $4.64M in shares on May 11, a bearish insider signal that partially offsets the bullish initiation. Overall, the call aligns with an already bullish consensus and is reinforced by positive earnings momentum and heavy institutional accumulation.

Impact Score

Consensus & Targets

Of 24 analysts covering ASND, 11 rate it Strong Buy, 12 rate Buy, and 1 rates Hold — a 95.8% Buy rating. There are zero Sell or Strong Sell ratings. Consensus is extremely bullish and has been consistently so.

Mean price target is $295.96, median is $287.46. High was $341.98 (prior to this initiation), low is $253.76. Citigroup's $355 target is 20% above the mean and 4% above the prior high. At the current price, implied upside to the mean is 20.5%, and to Citigroup's target is 44.6%.

Recent Analyst Activity

In the past 30 days, there has been 1 upgrade (this initiation) and 0 downgrades. EPS revisions are strongly positive: the current-year EPS estimate jumped from $2.82 to $10.21 over the past week, and the next-year estimate rose from $7.64 to $9.30. No downward revisions were recorded. Momentum is clearly bullish.

Firm Track Record — Citigroup

Citigroup accuracy: 55% on 4355 calls | avg return: 4.9%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 14 firms with ≥5 scored calls.

Citigroup has a 55% accuracy rate on 4,355 scored calls and an average return of 4.9%. Among firms covering ASND on a limited sample, the best track records belong to RBC Capital, Wedbush, UBS, TD Cowen, and Stifel, each with 100% accuracy on just 2-4 calls. BofA Securities and Oppenheimer have 80% accuracy on 5 calls. Citigroup's 75% accuracy on 4 ASND-specific calls is solid but not top-tier. The worst performers on ASND are Evercore ISI (67% on 3 calls, -0.7% avg return) and Goldman Sachs (33% on 3 calls, -0.2% avg return).

Earnings Estimates

Cross-Platform Signals

Insider activity: CEO Flemming Steen Jensen sold $4.64M on May 11, a notable sell by the C-suite that partially opposes the bullish initiation. Institutional flows are heavily bullish: Two Sigma added 34.8% and doubled another position, Morgan Stanley added 51.9% and 59.6%, and UBS doubled its stake. Short interest is extremely high at 91.5% (days to cover implied), suggesting heavy bearish bets that could squeeze on positive news. There is divergence between the insider sell and institutional buying, but the institutional and EPS momentum data dominate.

Documents Analyzed

Report based on filing metadata.

US Market Status